Stock listing
NASDAQ:FEMY Femasys Inc. Stock
Home listing (NASDAQ) of Femasys Inc.
Follow Femasys Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:FEMY
$1.24 USD +0.09 (+7.8%)
Close on Nov 20, 2026
- Day range
- $1.21 – $1.31 USDNov 20, 2026
- Volume
- 95,627 sharesNov 20, 2026
- Market cap
- $10.73M USDAt the close on Nov 20, 2026 · price × 8.66M shares outstanding
- 52-week range
- $1.07 – $20.80 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $296,881 USDMedian day 94,425 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FEMY · Home | $1.24 USD | +0.09 (+7.8%) | 95,627 | $1.31 | $1.31 | $1.21 | $1.15 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:FEMY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.24 | +0.09 | +7.8% | $1.31 | $1.31 | $1.21 | 95,627 | |
| $1.15 | +0.03 | +2.7% | $1.165 | $1.203 | $1.08 | 132,468 | |
| $1.12 | -0.16 | -12.5% | $1.29 | $1.305 | $1.07 | 110,551 | |
| $1.28 | -0.14 | -9.9% | $1.43 | $1.43 | $1.27 | 131,803 | |
| $1.42 | +0.02 | +1.4% | $1.46 | $1.54 | $1.40 | 52,304 | |
| $1.40 | -0.10 | -6.7% | $1.47 | $1.55 | $1.38 | 88,010 | |
| $1.50 | +0.07 | +4.9% | $1.44 | $1.53 | $1.42 | 81,909 | |
| $1.43 | +0.01 | +0.7% | $1.35 | $1.51 | $1.35 | 100,970 | |
| $1.42 | +0.05 | +3.6% | $1.435 | $1.482 | $1.39 | 71,834 | |
| $1.37 | +0.06 | +4.6% | $1.32 | $1.41 | $1.30 | 72,719 | |
| $1.31 | -0.13 | -9.0% | $1.41 | $1.42 | $1.255 | 109,961 | |
| $1.44 | +0.04 | +2.9% | $1.43 | $1.53 | $1.39 | 94,425 | |
| $1.40 | +0.08 | +6.1% | $1.34 | $1.44 | $1.33 | 160,081 | |
| $1.32 | -0.05 | -3.6% | $1.37 | $1.42 | $1.29 | 129,859 | |
| $1.37 | +0.015 | +1.1% | $1.33 | $1.41 | $1.31 | 95,116 | |
| $1.355 | -0.055 | -3.9% | $1.40 | $1.44 | $1.30 | 110,312 | |
| $1.41 | +0.04 | +2.9% | $1.41 | $1.44 | $1.38 | 63,420 | |
| $1.37 | -0.04 | -2.8% | $1.40 | $1.46 | $1.32 | 228,710 | |
| $1.41 | -0.09 | -6.0% | $1.47 | $1.50 | $1.361 | 110,573 | |
| $1.50 | -0.06 | -3.8% | $1.59 | $1.59 | $1.455 | 126,109 | |
| $1.56 | -0.09 | -5.5% | $1.66 | $1.68 | $1.46 | 167,719 | |
| $1.65 | -0.02 | -1.2% | $1.66 | $1.72 | $1.64 | 32,512 | |
| $1.67 | +0.04 | +2.5% | $1.65 | $1.77 | $1.58 | 34,001 | |
| $1.63 | -0.02 | -1.2% | $1.73 | $1.75 | $1.56 | 93,691 | |
| $1.65 | -0.085 | -4.9% | $1.70 | $1.77 | $1.60 | 58,500 | |
| $1.735 | +0.175 | +11.2% | $1.49 | $1.81 | $1.46 | 130,800 | |
| $1.56 | -0.20 | -11.4% | $1.74 | $1.75 | $1.465 | 208,700 | |
| $1.76 | +0.01 | +0.6% | $1.76 | $1.81 | $1.67 | 35,500 | |
| $1.75 | -0.25 | -12.5% | $2.00 | $2.02 | $1.71 | 66,500 | |
| $2.00 | -0.045 | -2.2% | $2.10 | $2.15 | $1.92 | 128,500 | |
| $2.045 | +0.045 | +2.2% | $1.99 | $2.11 | $1.94 | 67,700 | |
| $2.00 | -0.08 | -3.8% | $2.04 | $2.05 | $1.96 | 80,500 | |
| $2.08 | +0.06 | +3.0% | $2.07 | $2.11 | $2.01 | 24,100 | |
| $2.02 | -0.03 | -1.5% | $2.05 | $2.17 | $1.99 | 228,400 | |
| $2.05 | -0.05 | -2.4% | $2.16 | $2.19 | $1.96 | 252,600 | |
| $2.10 | -0.06 | -2.8% | $2.17 | $2.24 | $2.10 | 51,900 | |
| $2.16 | +0.07 | +3.3% | $2.19 | $2.24 | $2.09 | 114,300 | |
| $2.09 | -0.29 | -12.2% | $2.36 | $2.36 | $2.00 | 277,700 | |
| $2.38 | -0.10 | -4.0% | $2.42 | $2.485 | $2.35 | 20,700 | |
| $2.48 | +0.05 | +2.1% | $2.43 | $2.55 | $2.43 | 36,100 | |
| $2.43 | -0.15 | -5.8% | $2.53 | $2.616 | $2.42 | 103,300 | |
| $2.58 | +0.02 | +0.8% | $2.60 | $2.60 | $2.50 | 34,100 | |
| $2.56 | +0.03 | +1.2% | $2.55 | $2.69 | $2.55 | 73,200 | |
| $2.53 | -0.06 | -2.3% | $2.57 | $2.633 | $2.53 | 32,300 | |
| $2.59 | +0.04 | +1.6% | $2.51 | $2.64 | $2.51 | 35,000 | |
| $2.55 | +0.01 | +0.4% | $2.56 | $2.61 | $2.45 | 65,700 | |
| $2.54 | -0.02 | -0.8% | $2.61 | $2.736 | $2.509 | 79,400 | |
| $2.56 | -0.11 | -4.1% | $2.67 | $2.738 | $2.50 | 71,200 | |
| $2.67 | -0.11 | -4.0% | $2.84 | $2.848 | $2.59 | 29,800 | |
| $2.78 | +0.04 | +1.5% | $2.81 | $2.826 | $2.74 | 16,200 | |
| $2.74 | -0.09 | -3.2% | $2.90 | $2.95 | $2.68 | 35,500 | |
| $2.83 | +0.15 | +5.6% | $2.71 | $2.84 | $2.67 | 46,600 | |
| $2.68 | -0.30 | -10.1% | $2.99 | $3.086 | $2.60 | 197,700 | |
| $2.98 | -0.08 | -2.6% | $3.03 | $3.063 | $2.93 | 72,900 | |
| $3.06 | -0.04 | -1.3% | $3.10 | $3.18 | $3.01 | 56,700 | |
| $3.10 | -0.16 | -4.9% | $3.26 | $3.39 | $3.02 | 139,100 | |
| $3.26 | -0.17 | -5.0% | $3.34 | $3.425 | $3.213 | 66,800 | |
| $3.43 | +0.23 | +7.2% | $3.22 | $3.44 | $3.10 | 231,000 | |
| $3.20 | +0.41 | +14.7% | $2.79 | $3.35 | $2.74 | 530,400 | |
| $2.79 | -0.13 | -4.5% | $2.93 | $3.09 | $2.73 | 189,800 | |
| $2.92 | +0.07 | +2.5% | $2.88 | $3.00 | $2.83 | 110,400 | |
| $2.85 | -0.13 | -4.4% | $3.00 | $3.06 | $2.81 | 211,100 | |
| $2.98 | +0.02 | +0.7% | $2.94 | $3.08 | $2.86 | 294,400 | |
| $2.96 | +0.23 | +8.4% | $2.64 | $3.12 | $2.64 | 584,900 | |
| $2.73 | +0.02 | +0.7% | $2.59 | $2.82 | $2.43 | 961,700 |
Splits
1 split · NASDAQ:FEMY · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:FEMY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Latest deck · May 13, 2026
Investor Presentation (May 2026)
Investor deck · 24 slides
Latest news
Femasys Announces Financial Results for Quarter Ended September 30, 2026 and Provides Corporate Update
Nov 13, 2026
Closed $1.28 (-9.9%) on Nov 16, 2026
Femasys Appoints John Moorhead to Board of Directors
Oct 30, 2026
Closed $1.37 (+1.1%) on Oct 30, 2026
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
Oct 20, 2026
Closed $1.67 (+2.5%) on Oct 20, 2026
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
Oct 14, 2026
Closed $1.56 (-11.4%) on Oct 14, 2026
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
Oct 8, 2026
Closed $2.05 (+2.2%) on Oct 8, 2026
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
Sep 15, 2026
Closed $2.56 (-4.1%) on Sep 15, 2026
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
Sep 9, 2026
Closed $2.83 (+5.6%) on Sep 9, 2026
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
Aug 26, 2026
Closed $2.92 (+2.5%) on Aug 26, 2026
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
Aug 19, 2026
Closed $2.71 (+23.2%) on Aug 19, 2026
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
Aug 14, 2026
Closed $2.16 (-5.7%) on Aug 17, 2026
Femasys Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 29 in the last 12 months · 138 in all · newest Nov 13, 2026 · oldest 2021
- Decks
- 14 decks · latest May 13, 2026
Where Femasys Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FEMY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:FEMY | BOATS | United States | USD |
Valuation
EV/sales −4.2× against a median of 3.3×: the lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$8.31M USD
- P/E
- Loss
- EV/sales
- −4.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- 60.4%
- Operating margin
- −929.9%
- Net margin
- −614.7%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.60
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Femasys Inc. · NASDAQ:FEMY | US$10.73M | −US$8.31M | n/a | −4.2× | n/a | 0.4× | −614.7% | 0.2× | 1.60 |
| PetVivo Holdings Inc · OTC:PETV | US$11.76M | US$11.75M | n/a | 10.8× | n/a | n/a | −868.6% | n/a | 0.59 |
| Nosa Plugs AB · OMXSTO:NOSA | US$11.60M | US$10.20M | n/a | 3.3× | n/a | 3.1× | −24.5% | 0.1× | n/a |
| Observe Medical ASA · OSL:OBSRV | US$11.23M | US$12.45M | n/a | 6.5× | n/a | 3.7× | −258.6% | 0.7× | n/a |
| Arcoma AB · OMXSTO:ARCOMA | US$11.20M | US$8.23M | 23.5× | 0.7× | 6.6× | 1.5× | 4.0% | 0.0× | n/a |
| Health & Life Co., Ltd. · TPEX:1781 | US$10.93M | US$10.03M | n/a | 0.8× | n/a | 1.2× | −12.7% | 0.6× | n/a |
| ADM Tronics Unlimited, Inc. · OTC:ADMT | US$9.97M | US$9.77M | n/a | 3.0× | n/a | 13.4× | −4.3% | 0.0× | -1.45 |
| United Health Products, Inc. · OTC:UEEC | US$9.69M | US$9.69M | n/a | n/a | n/a | n/a | n/a | n/a | -0.09 |
| Guided Therapeutics, Inc. · OTC:GTHP | US$9.65M | US$9.68M | n/a | 14.2× | n/a | n/a | −445.9% | n/a | -0.75 |
| Nestmedic SA · NEWCONNECT:NST | US$9.65M | US$9.24M | n/a | 38.8× | n/a | 3.2× | −413.6% | 0.0× | n/a |
| EPS Bio Technology Corp. · TPEX:4183 | US$9.57M | US$5.77M | n/a | 0.4× | 21.4× | 1.2× | −1.6% | 0.0× | n/a |
| Median of the others | US$10.45M | US$9.73M | 23.5× | 3.3× | 14.0× | 3.1× | −24.5% | 0.0× | -0.42 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.60 · 2 analysts
- Revenue, year to Dec 2026
- 2.09M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kathy Lee-Sepsick | President and Chief Executive Officer |
| Dov Elefant | Chief Financial Officer |
| John Canning | Chief Operating Officer |
| James H. Liu | Chief Medical Officer |
| Jeffrey Mifek | Chief Clinical and Regulatory Affairs Officer |
| Jeremy Sipos | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| John Moorhead | Director |
| Kenneth D. Eichenbaum | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −9.9% |
| Q2 2026 | Aug 14, 2026 · After close | −5.7% |
| Q1 2026 | May 8, 2026 · After close | −6.0% |
| Q3 2025 | Nov 14, 2025 · After close | −11.4% |
| Q2 2025 | Aug 8, 2025 · After close | −13.2% |
| Q1 2025 | May 8, 2025 | −7.0% |
| Q4 2024 | Mar 27, 2025 · Before open | −12.2% |
| Q3 2024 | Nov 12, 2024 · Before open | −11.6% |
| Q2 2024 | Aug 8, 2024 · Before open | −18.1% |
| Q1 2024 | May 9, 2024 · Before open | −8.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 28, 2024 · After close | +11.0% |
| Q3 2023 | Nov 14, 2023 · Before open | −10.6% |
| Q2 2023 | Aug 10, 2023 · Before open | −6.5% |
| Q1 2023 | May 11, 2023 · After close | −13.2% |
| Q4 2022 | Mar 30, 2023 · Before open | −4.2% |
| Q3 2022 | Nov 10, 2022 · Before open | +6.0% |
| Q2 2022 | Aug 10, 2022 · After close | −8.1% |
| Q1 2022 | May 11, 2022 · After close | +2.8% |
| Q4 2021 | Mar 24, 2022 · After close | −3.9% |
| Quarter to Sep 30, 2021 | Nov 10, 2021 · After close | +2.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2026) | Investor deck | 24 slides | May 13, 2026 |
| Investor Presentation (October 2024) | Investor deck | 27 slides | Oct 29, 2024 |
| Investor Presentation (August 2024) | Investor deck | 27 slides | Aug 30, 2024 |
| Investor Presentation (April 2024) | Investor deck | 29 slides | April 2024 |
| Investor Presentation (September 2023) | Investor deck | 35 slides | Sep 27, 2023 |
| Investor Presentation (June 2023) | Investor deck | 41 slides | Jun 26, 2023 |
| Investor Presentation (May 2023) | Investor deck | 41 slides | May 11, 2023 |
| Investor Presentation (March 2023) | Investor deck | 43 slides | Mar 31, 2023 |
| Investor Presentation (October 2022) | Investor deck | 41 slides | Oct 20, 2022 |
| Investor Presentation (August 2022) | Investor deck | 40 slides | Aug 2, 2022 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2022) | Investor deck | 40 slides | Jul 28, 2022 |
| Investor Presentation (February 2022) | Investor deck | 36 slides | Feb 28, 2022 |
| Investor Presentation (January 2022) | Investor deck | 36 slides | Jan 5, 2022 |
| Investor Presentation (July 2021) | Investor deck | 27 slides | Jul 13, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants with accompanying warrants Closed: US$30M raised · US$3.2 a share · Warrants at US$2.95 for 36 months · Laidlaw & Company (UK) Ltd. +1 Dealers: Laidlaw & Company (UK) Ltd. (lead), Lake Street Capital Markets, LLC Buyers: Nantahala Capital (Led the financing as new institutional investor); Rosalind Advisors, Inc. Insiders: Members of Femasys' management team participated. Use of proceeds: Support strategic priorities: executing commercial initiatives, advancing clinical programs and key operational objectives | Aug 14, 2026 |
| Public offering of financing Closed: US$8M raised · US$0.36 a share · Warrants at US$0.36 for 60 months · Jones +1 Dealers: Jones (co-lead), Laidlaw & Company (UK) Ltd. (co-lead) Buyers: Jorey Chernett Insiders: Certain officers bought 87,363 shares and accompanying warrants at $0.5151 per share and accompanying warrant Use of proceeds: To accelerate commercialization efforts for its FemaSeed and FemBloc fertility and birth control products | Sep 2, 2025 |
| Public offering of common stock Announced: US$0.85 a share · Jones Dealers: Jones (lead) Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses | May 30, 2025 |
| Private placement of common stock Announced: US$0.85 a share · Jones Dealers: Jones (lead) Insiders: Certain directors and officers buy at a price of $1.02 per share Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses | May 30, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$13.00 a share on Jun 17, 2021.
- Price
- US$13.00 a share
- Shares offered
- 2,650,000 shares of common stock
- Offering size
- US$34.5 million
- Underwriters' option
- Up to 397,500 more shares
- Listing
- FEMY on the Nasdaq Capital Market
- Underwriters
- Chardan, JonesTrading · In the order on the cover
- Shares delivered
- On or about Jun 22, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 12, 2021 |
| Filed publicly | May 14, 2021 |
| Amended once | Jun 14, 2021 |
| Shares registered with an exchange | Jun 14, 2021 |
| Declared effective by the SEC | Jun 17, 2021 |
| Final prospectus, with the price | Jun 21, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2021 |
| EFFECT · Notice that a registration is effective | Jun 17, 2021 |
| CERT · Exchange's certificate of listing | Jun 17, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| CORRESP · Letter to the SEC | Jun 15, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 14, 2021 |
| S-1/A · Registration statement, amended | Jun 14, 2021 |
| CORRESP · Letter to the SEC | May 14, 2021 |
| S-1 · Registration statement | May 14, 2021 |
| UPLOAD · Letter from the SEC | Mar 26, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Mar 17, 2021 |
| DRS/A · Draft registration statement, amended | Mar 17, 2021 |
| UPLOAD · Letter from the SEC | Mar 10, 2021 |
| DRS · Draft registration statement | Feb 12, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M | 1.04M | 929.1K |
| Cost of revenue | 872.4K | 544.9K | 380.1K | 441.9K | 370.4K | 306.5K | 223.7K |
| Gross profit | 1.42M | 1.08M | 691.9K | 764.3K | 809.3K | 731.4K | 705.4K |
| Research and development | 7.58M | 8.22M | 7.21M | 5.81M | 4.08M | 4.13M | 6.91M |
| Selling, general and administrative | 6.65M | 6.33M | 6.86M | 5.43M | 4.26M | 2.54M | 3.30M |
| Operating income | -17.6M | -17.8M | -14.5M | -11.6M | -8.34M | -6.93M | -11.6M |
| Depreciation and amortization | 342.0K | 297.3K | 483.5K | 561.2K | 591.1K | 679.7K | 1.09M |
| EBITDA | -17.2M | -17.5M | -14.0M | -11.0M | -7.75M | -6.25M | -10.5M |
| Interest expense | 1.89M | 1.60M | 165.4K | 13.5K | 19.2K | 12.6K | 9.97K |
| Income before tax | -18.6M | -18.8M | -14.2M | -11.4M | -7.53M | -6.91M | -11.3M |
| Income tax | 1.30K | 9.60K | 4.34K | 6.30K | 4.00K | 1.80K | 3.01K |
| Net income | -18.6M | -18.8M | -14.2M | -11.4M | -7.54M | -6.91M | -11.3M |
| Earnings per share, basic | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 | -7.20 | -19.17 |
| Earnings per share, diluted | -0.47 | -0.85 | -0.93 | -0.96 | -1.12 | -7.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.27M | 3.45M | 21.7M | 13.0M | 24.8M | 3.32M | 6.42M |
| Short-term investments | 0 | 998.8K | |||||
| Receivables | 616.6K | 488.4K | 98.9K | 77.5K | 84.3K | 125.8K | 83.6K |
| Inventory | 5.74M | 3.05M | 667.1K | 436.7K | 208.3K | 131.4K | 172.5K |
| Current assets | 16.5M | 8.02M | 23.2M | 14.1M | 25.6M | 3.86M | 8.04M |
| Property, plant and equipment | 1.90M | 1.60M | 1.11M | 1.48M | 1.60M | 1.83M | 3.86M |
| Total assets | 20.7M | 12.4M | 27.8M | 16.9M | 28.6M | 7.61M | 12.6M |
| Accounts payable | 1.83M | 1.42M | 1.14M | 510.8K | 445.5K | 674.3K | 481.1K |
| Current liabilities | 3.64M | 8.58M | 3.05M | 1.53M | 1.69M | 2.89M | 1.29M |
| Long-term debt | 3.18M | 4.26M | 182.5K | ||||
| Total debt | 4.70M | 7.44M | 6.70M | 543.7K | 990.2K | 2.06M | 1.71M |
| Total liabilities | 14.9M | 10.1M | 9.40M | 1.65M | 2.24M | 4.08M | 58.0M |
| Shareholders' equity | 5.87M | 2.30M | 18.4M | 15.2M | 26.3M | -51.8M | -45.4M |
| Shares outstanding | 2.98M | 23.4M | 21.7M | 11.9M | 11.8M | 993.1K | 588.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -18.7M | -19.4M | -11.3M | -10.7M | -7.93M | -4.93M | -11.0M |
| Capital spending | -525.0K | -761.7K | -143.9K | -407.5K | -306.9K | -8.35K | -696.5K |
| Free cash flow | -19.2M | -20.2M | -11.4M | -11.1M | -8.24M | -4.94M | -11.7M |
| Cash from investing | -630.1K | -847.8K | -143.9K | -407.5K | -306.9K | 968.3K | 12.3M |
| Cash from financing | 25.1M | 2.03M | 20.2M | -681.6K | 29.7M | 871.6K | -127.8K |
| Share buybacks | -60.8K | -230.0K | 0 | 153.2K | 2.63K | ||
| Change in cash | 5.81M | -18.3M | 8.75M | -11.8M | 21.5M | -3.09M | 1.18M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 2, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-3 · Registration statement | Sep 3, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 31, 2026 | Big-stake notice | SEC |
| D | Aug 20, 2026 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 11, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 24, 2026 | Current report | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 27, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 18, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 12, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jan 9, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 7, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2026 | Other filings | SEC |
| S-3 · Registration statement | Dec 31, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 5, 2025 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| D | Nov 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 8-K · Current report | Nov 7, 2025 | Material contract | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 8-K · Current report | Oct 21, 2025 | Current report | SEC |
| 8-K · Current report | Oct 17, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 26, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 26, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 21, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 19, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 19, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 12, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 8, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jul 9, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 3, 2025 | Material contract | SEC |
| S-3 · Registration statement | Jul 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 25, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| D | Jun 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 2, 2025 | Offer document | SEC |
| 424B5 · Prospectus | May 29, 2025 | Offer document | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 8-K · Current report | Mar 18, 2025 | Current report | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 26, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 26, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 8-K/A · Current report, amended | Nov 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 8-K · Current report | Aug 30, 2024 | Current report | SEC |
| 8-K · Current report | Aug 29, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 12, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 20, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Jun 7, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 26, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 24, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Apr 5, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 5, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 8-K · Current report | Mar 20, 2024 | Current report | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 8-K · Current report | Feb 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 6, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 11, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Dec 8, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 5, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 30, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 29, 2023 | Current report | SEC |
| 3 · Initial statement of ownership | Nov 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 22, 2023 | Insider trade | SEC |
| D | Nov 22, 2023 | Other filings | SEC |
| SC 13D · Big-stake notice | Nov 22, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 21, 2023 | Management or board change | SEC |
| 8-K · Current report | Nov 15, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 11, 2023 | Current report | SEC |
| 8-K · Current report | Oct 3, 2023 | Current report | SEC |
| 424B3 · Prospectus | Oct 3, 2023 | Offer document | SEC |
| 8-K · Current report | Sep 27, 2023 | Current report | SEC |
| 8-K · Current report | Sep 6, 2023 | Meeting outcome | SEC |
This page holds 200 of 347 filings. Open Filings
Cap table
Built by 6ix from Femasys Inc.’s releases · as of Nov 12, 2026
- Common shares
- 8,656,277
- Fully diluted
- 8,656,277
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 8,656,277 | Nov 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.95 · expire about Aug 2029 |
| Warrants · US$0.36 · expire about Aug 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 8,656,277 |
| Sep 30, 2026 | 8,656,277 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Keith J Kendall Other companies: Aquestive Therapeutics, Inc. (CEO and President, Director · Jul 24, 2018 – Mar 10, 2022 · Past) | Director · Jun 14, 2023 – Jun 14, 2023 · Past |
| Kenneth D. Eichenbaum Other companies: InfuSystems Holdings, Inc. (Director · Since at least May 16, 2024) | Director · Since at least Mar 18, 2026 |
| Wendy Perrow Other companies: Bioanalytical Systems Inc (Director · Dec 10, 2015 – Sep 10, 2019 · Past) | Director · Jan 19, 2022 – Jun 21, 2023 · Past |
| Charles Larsen | Director · Since at least Jun 17, 2021 |
| Christine E Thomas | Chief Reg & Clinical Officer · Oct 10, 2023 – Jan 28, 2025 · Past |
| Daniel Scott Currie | Chief Operating Officer · Since at least Jul 3, 2023 |
| Dov Elefant | Chief Financial Officer · Since at least Jul 3, 2023 |
| Edward R Uzialko | Director · Since at least Jun 17, 2021 |
| Gary Thompson | Director · Jun 17, 2021 – Jun 17, 2021 · Past |
| Hoskin Violet Alexandria Kelley | VP, Clinical & Medical Affairs · Jun 17, 2021 – Jun 17, 2021 · Past |
All 18 people
| Person | Seat |
|---|---|
| James H. Liu | Chief Medical Officer · Since at least Aug 21, 2025 |
| Jeffrey Mifek | Chief Clinical and Regulatory Affairs Officer · Since at least Jul 6, 2026 |
| Jeremy Sipos | Chief Technology Officer · Since at least Dec 16, 2025 |
| John Canning | Chief Operating Officer · Since at least Mar 30, 2026 |
| John Moorhead | Director · Since at least Oct 30, 2026 |
| Kathy Lee-Sepsick | Chief Executive Officer, Director · Since at least Aug 7, 2026 |
| Kathy Lee-Sepsick | President and Chief Executive Officer · Since at least Aug 11, 2026 |
| Richard D Spector | Chief Commercial Officer · Feb 12, 2024 – Feb 12, 2024 · Past |
Log in to ask 6ix AI your own questions about Femasys Inc.